Dataset Information


Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans.

ABSTRACT: BACKGROUND: Cytochrome P4502C9 (CYP2C9) plays a vital role in drug metabolism. There has been an increased effort to identify polymorphisms within the gene and determine their clinical consequences. However, most of these efforts have focused on populations of European descent. Herein we report the influence of CYP2C9 genotype on warfarin dose among European American and African American patients. We also identify two new mutations; one in the coding region and one in the non-coding region of the CYP2C9 gene. METHODS: Patients (?20 years of age) are enrolled after obtaining medical, lifestyle and concomitant medication history. Changes in International Normalized Ratio (INR), warfarin dose, co-medications, diet, physical activity and the occurrence of complications are documented. CYP2C9 genotype was determined using PCR-RFLP and pyrosequencing. Differences in genotype frequencies and HWE assumptions were assessed using ?(2) statistics and exact tests. The genotype dose association was evaluated using multivariable linear regression. RESULTS: This report includes 490 patients (mean age 60.6 ± 15.6, 51.3% men). African American patients comprise 48.9% of the cohort with mean follow-up of 13.5 (±10.6) months. Both the CYP2C9 *2 and *3 allele were more frequent in European Americans (11.24%, 5.1%) compared to African Americans (1.1% and 1.8%). CYP2C9 *5 (0.9%), *6 (0.4%), and *11 (1.1%) variants were only observed in African Americans. The variant genotype is more frequent among European Americans compared to African Americans (29.8% vs. 9.73%, p<0.0001). Warfarin dose was significantly related to CYP2C9 genotype (p<0.0001) both in univariate and multivariate analyses. Multivariable race-specific analyses highlight the contribution of CYP2C9 genotype among European American but not among African American patients. CONCLUSION: The variant CYP2C9 genotype is more frequent among European Americans compared to African Americans. Among African Americans the variant genotype frequency is higher than previously reported. CYP2C9 genotype predicts warfarin dose in European Americans, but not in African Americans.


PROVIDER: S-EPMC2756088 | BioStudies | 2007-01-01

REPOSITORIES: biostudies

Similar Datasets

2008-01-01 | S-EPMC2757655 | BioStudies
2009-01-01 | S-EPMC2737687 | BioStudies
2009-01-01 | S-EPMC2789741 | BioStudies
2015-01-01 | S-EPMC4280295 | BioStudies
2010-01-01 | S-EPMC2904527 | BioStudies
2008-01-01 | S-EPMC2586955 | BioStudies
2013-01-01 | S-EPMC3759580 | BioStudies
2010-01-01 | S-EPMC2949912 | BioStudies
2016-01-01 | S-EPMC5300764 | BioStudies
2015-01-01 | S-EPMC7347085 | BioStudies